Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

PURPOSE: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GISTs). Imatinib, sunitinib and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Garner, Andrew P., Gozgit, Joseph M., Anjum, Rana, Vodala, Sadanand, Schrock, Alexa, Zhou, Tianjun, Serrano, Cesar, Eilers, Grant, Zhu, Meijun, Ketzer, Julia, Wardwell, Scott, Ning, Yaoyu, Song, Youngchul, Kohlmann, Anna, Wang, Frank, Clackson, Tim, Heinrich, Michael C., Fletcher, Jonathan A., Bauer, Sebastian, Rivera, Victor M.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233175/
https://ncbi.nlm.nih.gov/pubmed/25239608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1397
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים